Regenerative Medicine in Orthopaedics: New Therapy or Complementary Technique?

AOP Response: We have high hopes that advanced drug and gene/immune therapies will lead to revolutionary advancements. Unfortunately, currently, many of these therapies are limited by the FDA for use in the US. Many regenerative technologies are approved for treatment outside the US and in veterinary medicine, and we are staying abreast of the associated research. But the cost remains prohibitive, and questions endure about whether stem cells should be a standalone therapy or a complement to traditional orthopedic practices. AOP anticipates being an early adopter once biologics/cellular therapies are allowed more broadly in the US.